NasdaqGS:PETS

Stock Analysis Report

Executive Summary

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States.

Snowflake

Fundamentals

Flawless balance sheet established dividend payer.


Similar Companies

Share Price & News

How has PetMed Express's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.3%

NasdaqGS:PETS

-3.1%

US Online Retail

-1.6%

US Market


1 Year Return

-58.2%

NasdaqGS:PETS

-6.2%

US Online Retail

-3.0%

US Market

PETS underperformed the Online Retail industry which returned -6.2% over the past year.

PETS underperformed the Market in United States of America which returned -3% over the past year.


Share holder returns

PETSIndustryMarket
7 Day-6.3%-3.1%-1.6%
30 Day-4.2%-9.5%-5.7%
90 Day-15.1%0.3%0.2%
1 Year-56.1%-58.2%-6.2%-6.2%-0.8%-3.0%
3 Year-15.2%-23.5%84.9%84.7%38.1%29.1%
5 Year32.8%9.8%205.5%183.6%50.8%34.1%

Price Volatility Vs. Market

How volatile is PetMed Express's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PetMed Express undervalued based on future cash flows and its price relative to the stock market?

10.35x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

PetMed Express's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

PetMed Express's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

PetMed Express is good value based on earnings compared to the US Online Retail industry average.

PetMed Express is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

PetMed Express earnings are not expected to grow next year, we can't assess if its growth is good value.


Price Based on Value of Assets

PetMed Express is good value based on assets compared to the US Online Retail industry average.


Next Steps

Future Growth

How is PetMed Express expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

-0.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

PetMed Express's revenue is expected to grow by 1.7% yearly, however this is not considered high growth (20% yearly).

PetMed Express's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

PetMed Express's revenue growth is positive but not above the United States of America market average.

PetMed Express's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

PetMed Express's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if PetMed Express will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has PetMed Express performed over the past 5 years?

19.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

PetMed Express's year on year earnings growth rate has been positive over the past 5 years.

PetMed Express's 1-year earnings growth is negative, it can't be compared to the 5-year average.

PetMed Express's 1-year earnings growth is negative, it can't be compared to the US Online Retail industry average.


Return on Equity

PetMed Express has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

PetMed Express used its assets more efficiently than the US Online Retail industry average last year based on Return on Assets.


Return on Capital Employed

PetMed Express's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is PetMed Express's financial position?


Financial Position Analysis

PetMed Express is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

PetMed Express's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

PetMed Express has no debt.

PetMed Express has not taken on any debt in the past 5 years.

PetMed Express has no debt, it does not need to be covered by operating cash flow.

PetMed Express has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

PetMed Express has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is PetMed Express's current dividend yield, its reliability and sustainability?

7.21%

Expected Dividend Yield


Dividend Yield and Payments Analysis

PetMed Express's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.52%).

PetMed Express's dividend is above the markets top 25% of dividend payers in United States of America (3.93%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are covered by earnings (1.4x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of PetMed Express's salary, the management and board of directors tenure and is there insider trading?

16.4yrs

Average board tenure


CEO

Menderes Akdag (58yo)

18.4yrs

Tenure

US$857,551

Compensation

Mr. Menderes Akdag has been the Chief Executive Officer of PetMed Express, Inc. since March 16, 2001 and has been its President since August 2005. Mr. Akdag has a breadth of experience in the areas of dire ...


CEO Compensation Analysis

Menderes's remuneration is lower than average for companies of similar size in United States of America.

Menderes's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

16.4yrs

Average Tenure

72yo

Average Age

The average tenure for the PetMed Express board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$277,50014 Sep 18
Robert Schweitzer
EntityIndividual
Role
Chairman of the Board
Chairman
Shares7,500
Max PriceUS$37.00

Ownership Breakdown


Management Team

  • Menderes Akdag (58yo)

    CEO, President & Director

    • Tenure: 18.4yrs
    • Compensation: US$857.55k
  • Bruce Rosenbloom (50yo)

    CFO & Treasurer

    • Tenure: 18.3yrs
    • Compensation: US$866.28k
  • Alison Berges

    Corporate Secretary & General Counsel

    • Tenure: 0.0yrs

Board Members

  • Gian Fulgoni (71yo)

    Director

    • Tenure: 16.8yrs
    • Compensation: US$305.73k
  • Menderes Akdag (58yo)

    CEO, President & Director

    • Tenure: 18.4yrs
    • Compensation: US$857.55k
  • Ronald Korn (79yo)

    Director

    • Tenure: 16.8yrs
    • Compensation: US$305.73k
  • Bob Schweitzer (73yo)

    Chairman

    • Tenure: 13.1yrs
    • Compensation: US$305.73k
  • Frank Formica (75yo)

    Independent Director

    • Tenure: 16.0yrs
    • Compensation: US$305.73k
  • Leslie C. Campbell (61yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$305.73k

Company Information

PetMed Express, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PetMed Express, Inc.
  • Ticker: PETS
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Internet and Direct Marketing Retail
  • Sector: Retail
  • Market Cap: US$309.585m
  • Shares outstanding: 20.02m
  • Website: https://www.1800petmeds.com

Number of Employees


Location

  • PetMed Express, Inc.
  • 420 South Congress Avenue
  • Delray Beach
  • Florida
  • 33445
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PETSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 1997
PQMDB (Deutsche Boerse AG)YesCommon StockDEEURSep 1997

Biography

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 23:44
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.